Predictive value of the Ki67 index for lymph node metastasis of small non-functioning pancreatic neuroendocrine neoplasms.
Adult
Aged
Aged, 80 and over
Biomarkers, Tumor
/ analysis
Female
Humans
Ki-67 Antigen
/ analysis
Lymph Node Excision
Lymphatic Metastasis
Male
Mesenteric Artery, Superior
/ pathology
Middle Aged
Neuroendocrine Tumors
/ diagnosis
Pancreatic Neoplasms
/ diagnosis
Predictive Value of Tests
Tomography, X-Ray Computed
Dissection
Ki67
Lymph node metastasis
Non-functioning
Small PanNEN
Journal
Surgery today
ISSN: 1436-2813
Titre abrégé: Surg Today
Pays: Japan
ID NLM: 9204360
Informations de publication
Date de publication:
Jul 2019
Jul 2019
Historique:
received:
13
12
2018
accepted:
12
01
2019
pubmed:
7
3
2019
medline:
18
12
2019
entrez:
7
3
2019
Statut:
ppublish
Résumé
We evaluated the clinicopathological factors associated with lymph node metastasis in patients with non-functioning pancreatic neuroendocrine neoplasms (PanNENs), focusing on the risk factors and range of lymph node metastasis for tumors ≤ 2 cm in diameter. The subjects of this study were patients with PanNENs consecutively diagnosed at our hospital between January, 2000 and June, 2018. We analyzed 69 patients who underwent R0 resection of a non-functioning sporadic PanNEN with no distant metastasis, as well as 43 patients with tumors ≤ 20 mm in radiological diameter. Nineteen patients (27.5%), including 7 (16.3%) with a small PanNEN, had lymph node metastasis. A large radiological diameter, a high Ki67 index, and cyst formation correlated significantly with positive lymph node metastasis. In patients with tumors ≤ 20 mm in diameter, a high Ki67 index correlated significantly with lymph node metastasis. When we set the cut-off Ki67 index as 3.3%, 2 of 43 patients had lymph node metastasis. Tumors in the uncinate process readily metastasized to the region around the superior mesenteric artery. These findings suggest that a high Ki67 index indicates a risk of lymph node metastasis for tumors ≤ 20 mm in diameter and that lymphadenectomy should be performed in the region spatially adjacent to the primary tumor.
Sections du résumé
BACKGROUND
BACKGROUND
We evaluated the clinicopathological factors associated with lymph node metastasis in patients with non-functioning pancreatic neuroendocrine neoplasms (PanNENs), focusing on the risk factors and range of lymph node metastasis for tumors ≤ 2 cm in diameter.
METHODS
METHODS
The subjects of this study were patients with PanNENs consecutively diagnosed at our hospital between January, 2000 and June, 2018. We analyzed 69 patients who underwent R0 resection of a non-functioning sporadic PanNEN with no distant metastasis, as well as 43 patients with tumors ≤ 20 mm in radiological diameter.
RESULTS
RESULTS
Nineteen patients (27.5%), including 7 (16.3%) with a small PanNEN, had lymph node metastasis. A large radiological diameter, a high Ki67 index, and cyst formation correlated significantly with positive lymph node metastasis. In patients with tumors ≤ 20 mm in diameter, a high Ki67 index correlated significantly with lymph node metastasis. When we set the cut-off Ki67 index as 3.3%, 2 of 43 patients had lymph node metastasis. Tumors in the uncinate process readily metastasized to the region around the superior mesenteric artery.
CONCLUSIONS
CONCLUSIONS
These findings suggest that a high Ki67 index indicates a risk of lymph node metastasis for tumors ≤ 20 mm in diameter and that lymphadenectomy should be performed in the region spatially adjacent to the primary tumor.
Identifiants
pubmed: 30838442
doi: 10.1007/s00595-019-01779-9
pii: 10.1007/s00595-019-01779-9
doi:
Substances chimiques
Biomarkers, Tumor
0
Ki-67 Antigen
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
593-600Subventions
Organisme : Japan Society for the Promotion of Science
ID : JP18K08677
Références
World J Surg. 2002 Oct;26(10):1267-71
pubmed: 12205558
J Gastroenterol. 2010 Feb;45(2):234-43
pubmed: 20058030
Dig Dis Sci. 1991 Jul;36(7):933-42
pubmed: 2070707
Endocrinol Metab Clin North Am. 2011 Mar;40(1):1-18, vii
pubmed: 21349409
Surgery. 2011 Jul;150(1):75-82
pubmed: 21683859
HPB (Oxford). 2012 Mar;14(3):171-6
pubmed: 22321035
J Gastroenterol. 2012 Jun;47(6):678-85
pubmed: 22350698
Pancreas. 2012 Aug;41(6):840-4
pubmed: 22781907
Surgery. 2012 Dec;152(6):965-74
pubmed: 23102679
Langenbecks Arch Surg. 2013 Mar;398(3):431-40
pubmed: 23143147
Ann Surg Oncol. 2013 Sep;20(9):2815-21
pubmed: 23771245
Endoscopy. 2014 Jan;46(1):32-8
pubmed: 24218309
Ann Surg. 2014 Feb;259(2):197-203
pubmed: 24253141
Pancreas. 2014 May;43(4):526-31
pubmed: 24658317
Cytopathology. 2014 Dec;25(6):389-95
pubmed: 24750272
Ann Surg Oncol. 2014 Oct;21(11):3515-21
pubmed: 24841347
Am J Surg. 2014 Nov;208(5):775-780
pubmed: 24997491
J Gastrointest Surg. 2015 Jan;19(1):117-23; discussion 123
pubmed: 25155459
J Gastrointest Surg. 2016 Dec;20(12):1966-1974
pubmed: 27714644
Neuroendocrinology. 2017 Feb 25;105(3):255-265
pubmed: 28237989
Ann Surg Oncol. 2018 Feb;25(2):528-534
pubmed: 29164413
Sci Rep. 2018 May 8;8(1):7271
pubmed: 29739948
J Natl Compr Canc Netw. 2018 Jun;16(6):693-702
pubmed: 29891520
Arch Surg. 1993 Oct;128(10):1143-8
pubmed: 8105769